OBJECTIVES: Left ventricular assist devices (LVADs) are a routine treatment for patients with advanced heart failure as a bridge to transplantation. The aim of this study was to present our institutional experience and mid-term outcomes after implantation of 139 continuous-flow (cf ) LVADs as a bridge to transplantation.
INTRODUCTION
Cardiac transplantation remains the gold standard therapy for patients with end-stage heart failure despite increased waiting times and mortality due to donor organ shortage [1] . Left ventricular assist devices (LVADs) are now routine treatment for patients with advanced heart failure as a bridge to transplantation with many patients undergoing LVAD implantation as a bridge to recovery or destination therapy [2, 3] .
Current LVADs are continuous-flow (cf ) pumps, which are smaller, quieter and more reliable than previous generation LVADs [4] . However, even though a newer generation of partial support devices has become available on the market, the number of implantations of these LVADs has been limited by the need for certain technological adjustments, and full support cfLVADs still remain the most widely used assist systems in the current era [5, 6] .
The present population of patients with end-stage heart failure requiring LVAD support is gradually becoming more demanding in terms of an increasing proportion of high-risk patients. This might be explained by the fact that a substantial number of the patients are already on mechanical support and need an LVAD exchange due to device failure. Furthermore, the number of patients awaiting cardiac transplantation is permanently increasing, leading to a higher number of patients who become unstable and need inotropic and intra-aortic balloon pump (IABP) support or extracorporeal membrane oxygenation (ECMO) support [7] .
The aim of the present study was to analyse our institutional experience with cfLVADs as a bridge to transplantation in a 'real-world' cohort with all LVAD implantations, including both firsttime implantations and VAD exchanges.
PATIENTS AND METHODS

Study population
The study design was a retrospective review of the prospectively collected data and did not require ethical approval. The database represents a part of the national VAD surgery data collection and outcome evaluation in the UK. Included were 139 consecutive patients who underwent cfLVAD implantation either with the HeartMate II (HM II) (Thoratec Corporation, Pleasanton, CA, USA) or the HVAD® Pump (HeartWare, Inc., Framingham, MA, USA) between July 2007 and August 2013 in Harefield Hospital. As the chronic support LVAD therapy is currently not funded in the UK, we did not perform any LVAD implantations as a destination therapy. Prospectively collected data included detailed information on patients' demographics and baseline clinical characteristics, laboratory, echocardiographic and haemodynamic parameters, as well as intraoperative variables and postoperative outcomes.
Definitions
Liver failure was defined as the presence of at least two liver function parameters with 2-fold elevation of the upper normal range. Any postoperative renal dysfunction that required dialysis/haemofiltration was defined as renal failure. Respiratory failure was defined as any impairment of respiratory function requiring reintubation or mechanical ventilation that occurred since LVAD implantation. Any right heart failure after LVAD implantation resulting in clinical instability and requiring implantation of a short-or long-term right ventricular assist device (RVAD) was defined as right ventricular failure (RVF).
Surgical techniques
Most cfLVAD implantations were performed through a standard median sternotomy, either off-pump (n = 19, 14%) or with cardiopulmonary bypass (CPB) through cannulation of the ascending aorta and right atrium, either on beating heart (n = 94, 68%) or with cardioplegic arrest (n = 17, 17%). Patients who were on ECMO support as a bridge to decision prior to cfLVAD implantation were supported with CPB which was connected to the ECMO cannulas intraoperatively (n = 9, 7%). Four patients underwent a minimally invasive HeartWare implantation through a leftsided anterior thoracotomy (8 cm) using CPB, the details of which are described elsewhere [8] .
Driveline placement
In most cases, driveline placement was performed using the conventional surgical technique penetrating the skin after a short subfascial course directly under the right subcostal margin. An alternative double-tunnel technique, which consists of a long C-shaped subfascial route and is supposed to prevent percutaneous site infections (PSIs), was applied in 26 (19%) cases. The low rate of this alternative technique in our patient cohort can be explained by the fact that this strategy was a preference of one of the implanting surgeons at our centre.
Anticoagulation protocol
Intravenous heparin application to maintain the activated partial thromboplastin time between 50 and 70 s was first commenced after a minimum of 12 h post-implant, when the cumulative chest tube drainage fell to less than 50 ml per hour and the coagulation profile returned to normal or near-normal levels. Also, similar to most mechanical circulatory support (MCS) centres, we also used platelet aggregation inhibitors as a part of our anticoagulation protocol. Seventy-five milligram of aspirin daily was immediately started after extubation. After chest drain removal and tolerance of oral medication, warfarin was administered to maintain the international normalized ratio (INR) between 2.0 and 3.0. The heparin infusion was continued until the INR range was attained. In cases when the INR dropped below 2.0 and patients were not on heparin infusion, low-molecular heparin (Clexane®) was used in a usual dose of 1 mg/kg body weight to ensure an appropriate anticoagulation status during this time period.
Statistical analysis
All data were analysed using IBM SPSS Statistics for Windows, Version 21 (IBM Corp. Released 2012. Armonk, NY: IBM Corp.) and are presented as continuous or categorical variables. Continuous data were evaluated for normality using a one-sample KolmogorovSmirnov test and confirmed by histograms. Continuous variables were expressed as the mean ± standard deviation (SD) in cases of normally distributed variables or the median (interquartile range) in cases of non-normally distributed variables. Categorical variables are presented as total numbers of patients and percentages. Continuous data were analysed with the unpaired t-test for normally distributed variables and the Mann Whitney U-test for nonnormally distributed variables variables. Pearson's χ² or Fisher's exact tests were used for categorical data dependent on the minimum expected count in each cross tab. Laboratory test changes over the perioperative course were analysed with a paired t-test for normally distributed variables. Kaplan-Meier survival estimation was applied for survival analysis of the entire patient cohort. Patients who underwent cardiac transplantation, device exchange for device failure or device explantation for myocardial recovery were censored. A log-rank (Mantel-Cox) test was applied for comparison of cumulative survival estimates of patients who underwent their first cfLVAD implantation with those who were already on any mechanical support and underwent device exchange in this study. P-values <0.05 were considered statistically significant. Propensity score (PS) matching in SPSS software was conducted to reduce a confounding bias between the groups. A PS for each patient was estimated using a logistic regression model with device type as the dependent variable and preoperative characteristics that were statistically significant in overall comparison as independent variables. Matching was based on a one-to-one nearest neighbour matching method with a tolerance level on the maximum PS distance (calipers of width 0.2 SDs of the logit of the PS). This PS-based matching procedure resulted in a total number of 50 patients (25 pairs) supported with HM II or HeartWare LVADs, who were well matched for baseline characteristics.
RESULTS
Patient's demographics and preoperative baseline characteristics
Patient's demographics and preoperative baseline characteristics are presented in Table 1 . The mean age of the population was 44.0 ± 13.7 years and 24 (17%) patients were female. Table 2 represents preoperative haemodynamic, echocardiographic and laboratory characteristics. A substantial proportion of the patients were on preoperative inotropic or mechanical support. Of the total number of patients in our study, 73% were pre-optimized with i.v. milrinone that was started 2-7 days before LVAD implantation. Some patients required additional inotropes, mainly adrenalin to boost the right ventricular function, whereas some patients with advanced heart failure affecting end-organ perfusion were optimized with an IABP (25%), short-term MCS (9%) or extracorporeal membrane oxygenator (ECMO) (18%).
Postoperative major adverse events
Intraoperative characteristics and postoperative outcomes including major adverse events after LVAD implantation are presented in Table 3 . Twenty-three (17%) patients required postoperative surgical revision for various reasons: 20 (14%) for bleeding, 1 (1%) for pleural haematoma compromizing ventilation, 1 (1%) for a pulmonary embolus and 1 (1%) for the repositioning of the LVAD cannula due to persistent suction events.
Long-term outcomes and causes of death
Over the follow-up period, 19 patients (14%) were successfully transplanted, 20 (14%) underwent LVAD explantation for myocardial recovery, 14 (10%) underwent device exchange for device failure and 39 (28%) are still being supported. All patients were supported as a bridge to transplantation; however, due to organ shortage a significant proportion of patients have not been transplanted yet. Fourty-seven patients (34%) died on support during the follow-up-period. The most common causes of death were multiorgan failure (n = 12, 26%) followed by intracranial bleeding (n = 11, 23%), sepsis (n = 6, 13%) and ischaemic stroke (n = 4, 9%). Other causes of death are presented in Table 4 . In 5 patients, the cause of death was uncertain and was related to a sudden collapse of unknown reason.
Device-related infections: incidence and treatment strategies
Thirty-five patients (25%) experienced a PSI during the follow-up: 8 (6%) fungal, 27 bacterial (19%); all of them required i.v. antibiotic or antifungal treatment, whereas 11 (8%) patients required surgical drainage and vacuum-assisted closure. All the fungal infections were caused by Candida albicans and bacterial PSIs were caused by various pathogens (Table 5 ). In 23 patients with PSI, ultrasound examination showed driveline tunnel collections (mean diameter 17 ± 9 mm). The surgical drainage and vacuum-assisted closure was usually performed for driveline tunnel collections >10 mm in diameter. Furthermore, 2 patients developed a device pocket infection. The first infection was caused by bacterial pathogens (Staphylococcus aureus and Coliform)-the patient was placed on the national urgent waiting list and subsequently transplanted. The second infection caused by C. albicans was occult and only recognized after device explantation during LVAD exchange for device thrombosis.
Follow-up and survival
The mean support duration was 514 ± 481 days. The longest support was 2493 days (>6 years); this patient is currently still on ongoing support and doing well. The overall cumulative survival rate after cfLVAD was 89% at 30 days, 76% at 1 year and 66% at 2 years ( Fig. 1) . As we did not exclude patients who were on preoperative VAD support and have a higher risk of mortality, we performed a comparison of survival between patients who underwent first-time cfLVAD with those who underwent VAD exchange (Fig. 2 ). There was a statistically significant difference in survival in favour of first LVAD implantation in Kaplan-Meier survival estimates: 91 vs 80% at 30 days, 79 vs 57% at 1 year and 70 vs 43% at 2 years (log-rank P = 0.010). 
Postoperative changes in end-organ function
To assess the influence of cfLVAD support on end-organ function, we analysed the perioperative trend of hepatic (total bilirubin and alanine aminotransferase) and renal (serum creatinine and blood urea nitrogen) function tests. There was a significant improvement in all four parameters 1 month after cfLVAD implantation, reflecting a considerable improvement in end-organ function (Fig. 3) .
Comparison of HeartMate II versus HeartWare matched by propensity score analysis
During the observational period, two types of cfLVADs were implanted in our centre: 72 (52%) patients underwent HM II and 67 (48%) HeartWare implantation. The direct comparison of the devices revealed statistically significant differences in a number of preoperative variables potentially biasing patients' outcome. To minimize the potential effects of selection bias on patient characteristics of those treated with two different devices, we performed a one-to-one PS matching, whereas a total number of 50 patients remained for the analysis. Unlike the variability of both groups in the entire population, these two propensity-matched groups were well balanced, and no significant differences were observed in demographic and preoperative baseline characteristics including haemodynamic, echocardiographic, laboratory and other clinical variables.
Intraoperatively, there were no statistically significant differences in the rate of off-pump LVAD implantation (P = 0.60) and placement of the driveline using a conventional or double-tunnel technique (P = 0.30). CPB time was also statistically not different between the two groups (P = 0.11).
Postoperatively, HM II patients had a significantly higher use of fresh frozen plasma [2(2;11) vs 2(0;4) units, P = 0.020], and there was a trend towards a higher use of red blood cells [6(2;9) vs 2(1;8) units, P = 0.094] in the HM II group; however, there were no differences in the incidence of resternotomy for bleeding or chest haematoma (P = 0.36). The groups were comparable in the requirement of prolonged (>7 days) mechanical ventilation (P = 1.00) and prolonged inotropic support (P = 0.35), RVF requiring RVAD implantation (P = 0.46), need for extracorporeal membrane oxygenation (ECMO) support (P = 1.00) and renal failure requiring renal replacement therapy (P = 0.55). The rate of respiratory failure (P = 0.67), need for tracheostomy (P = 0.35), intensive care unit length of stay (LOS, P = 0.94) and total hospital LOS (P = 0.90) were similar in both groups. While there were no statistically significant differences in the incidence of postoperative sepsis (P = 0.52) and broncho-pulmonary infections (P = 0.20), HM II patients were more likely to develop PSI requiring at least antibiotic therapy (40 vs 8%, P = 0.022). The incidence of PSI requiring surgical treatment (P = 1.00) was similar in the two groups.
There was no significant difference in cumulative survival (log-rank P = 0.30), and the proportion of patients who were transplanted (P = 0.19), died on support (P = 0.15), explanted for myocardial recovery (P = 0.67), underwent device exchange for pump failure (P = 1.00) or remained on ongoing support (P = 0.33) at the cut-off of the study. The incidence of cerebrovascular accidents (P = 0.50) was also similar in groups (Supplementary Tables 1-5 ).
DISCUSSION
This study is a single-centre analysis of cfLVAD implantations as a bridge to transplantation over 6 years with the main focus on survival and postoperative complications. Over the last decade, the number of VADs implanted, duration of support and survival have increased significantly [9] . The 2-year survival rate after LVAD implantation became similar to that of heart transplant [10, 11] . However, the long-term survival remains relatively poor, as LVAD implantation is still associated with significant postoperative adverse events [4] . Early complications include surgical bleeding, infections, arrhythmias, air embolism and RVF. Late major complications precluding long-term LVAD support are primarily associated with device-related infections, such as PSI or device pocket infections, anticoagulation-related complications, aortic regurgitation, thromboembolism and primary device failure. Nevertheless, LVADs are still considered the best option for a bridge to cardiac transplantation but are yet to be accepted widely as a destination therapy. In the present study, the survival rates at 1 and 2 years were 76 and 66%, respectively, which are inferior to the survival rates in patients in previous trials with 1-and 2-year survival rates of 84 and 79% [10] and a 1-year survival rate of 86% [12] . However, the stringent patient inclusion criteria in the previous trials differ markedly from those in the present series. Advanced chronic heart failure or acute cardiogenic shock refractory to medical treatment with IABP, multiple inotropes and vasoconstrictors represents an indication for a short-term MCS [12] . This study analyses a real-world 'all-comer' experience including patients on preoperative inotropic or mechanical support. Short-term MCS was used as a salvage therapy with the goal of restoring haemodynamic stability and end-organ function; however, it is reported that an upgrade to an LVAD in such patients is associated with significantly increased mortality [12] . Furthermore, the proportion of patients in INTERMACS level I and II in previous series is only 22-29%, whereas it comprises 60% of our study population. Additionally, inclusion of elderly patients has also influenced the outcomes of the present series. On the other hand, the survival in the present series is comparable to the contemporary studies, which represent the 'real-world' experience [3, 7] .
An important complication following institution of LVAD therapy is RVF, manifested by the need for prolonged inotropic support and the need for right-sided MCS in moderate to severe and therapy-refractory cases. The incidence rate of right ventricular dysfunction after LVAD implantation that fails to resolve in the operating room is reported to be as frequent as 20-50%, increasing the mortality rate from 19 to 43%. Although most patients can be maintained with prolonged inotropic support, 10-15% may require implantation of a separate right ventricular support device [13] . In this study, RVAD support was used in 23% of patients. This might be explained by our aggressive RVF treatment approach and good clinical results using CentriMag (Thoratec Corporation) extracorporeal short-term circulatory support [14] . Also, optimization of patients before LVAD implantation was key to avoiding postoperative RVF. We have previously shown that the optimization of preoperative volume status, preload and right heart function is a critical factor influencing early outcome after cfLVAD implantation [15] .
One of the most significant late postoperative complications reported in our study was device failure related to pump thrombosis. Device thrombosis is a result of either in situ device thrombogenesis with a gradual reduction in flow and an increase in power, or migration of thrombus formations into the inflow cannula with rapid dramatic changes [16] . Thrombosis in the LVAD pumps is an infrequent but potentially life-threatening complication due to a high mortality related to its treatment. Currently, there is still no consensus in terms of device thrombosis management; however, thrombolytic therapy is favoured as a first line of treatment [17] . Several groups have suggested intracavitatory thrombolytic therapy through a catheter in the left ventricle with the view to reduce its systemic side effects [16] . However, Aissaoui et al. disagree on the benefits of thrombolytic therapy and prefer device exchange, though associated with significantly higher mortality [18, 19] . In this series, all patients with device failures underwent a surgical LVAD exchange through median sternotomy with an aceptable outcome. Furthermore, there are few reports in the literature on pump exchange using minimally invasive access with similar outcomes compared with full sternotomy [18, 20] . However, due to a higher mortality in this challenging patient group, minimally invasive access for LVAD exchange represents a surgical challenge and is limited to experienced high-volume centres. Nevertheless, there are sparse data comparing surgical pump exchange with thrombolytic therapy, and the choice largely remains an individual/institutional preference.
Infection-related complications were the most common adverse event, mainly late device-related infections, in 27% of patients in this study. Interestingly, the double-tunnel driveline placement technique was not associated with lower incidence of PSI. Facing this serious and sometimes life-threatening complication, apart from prevention policies, we developed a step-by-step diagnostic and treatment strategy in our institution which includes local care, i.v. antibiotic treatment, surgical debridement and vacuum dressings up to extended surgical interventions, if necessary.
There was a relatively small proportion of patients who were transplanted over the follow-up period though comparable to that of previous research. The reason for this might be explained by the discrepancy of a relatively high number of patients supported and significant organ shortage. However, due to ongoing technological progress in the transplant area and availability of alternative preservation and assessment strategies, such as the organ care system (OCS), the number of organs transplanted in our centre increases every year as this system increases the donor pool by utilizing organs previously not considered for transplantation. Particularly, LVAD patients benefit from the OCS as the system allows optimization of logistics and meticulous preparation of the recipients with LVADs/previous sternotomy.
We also analysed potential differences in outcomes after implantation of HM II and HVAD using PS matching. The HM II is an axially configured pump with the rotor being parallel to the flow direction [5] . The HVAD utilizes a centrifugal blood pump, which provides flow using hydrodynamic and centrifugal forces. The devices contain only one electromagnetically suspended moving part resulting in great durability and can generate up to 10 l/min flow. Owing to its smaller size and weight, the HVAD is usually implanted intrapericardially without the need for additional pump pocket formation [4] . In contrast, the HM II is usually placed in a preperitoneal location requiring an LVAD pocket. In our study, there were no significant differences in most postoperative variables between the two groups. However, HM II patients had a significantly higher perioperative transfusion rate. This might be caused by a slightly more invasive implantation technique due to the necessity of pump pocket formation during HM II implantation. Nevertheless, a higher transfusion rate did not lead to a higher incidence of re-exploration for bleeding or haematoma in the HM II group, or impact overall survival. However, a more invasive HM II implantation technique may contribute to a significantly higher rate of PSI in the HM II group, despite comparable rates of diabetes mellitus and the use of alternative double-tunnel technique for driveline placement in the two groups.
In summary, we present outcomes and adverse events after cfLVAD implantation as a bridge to transplantation for all patients, reflecting everyday practice. The survival of a substantial proportion of patients with advanced heart failure awaiting heart transplantation can be significantly improved using cfLVAD support before a suitable organ becomes available. Moreover, due to the current organ scarcity, MCS may be the only chance of survival for patients in critical situations, such as previous device failure, haemodynamic instability and cardiogenic shock. Some of these patients can be bridged to a long-term cfLVAD using short-term MCS. However, despite excellent results and improved quality of life after cfLVAD implantation, perioperative complications such as device thrombosis, RVF and device-related infections remain major issues that need to be addressed to further optimize outcomes.
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